{"id":"https://openalex.org/W7026539006","doi":null,"title":"Anticorpos bloqueadores dos checkpoints imunes","display_name":"Anticorpos bloqueadores dos checkpoints imunes","publication_year":2014,"publication_date":"2014-01-01","ids":{"openalex":"https://openalex.org/W7026539006"},"language":"pt","primary_location":{"id":"pmh:oai:repositorio.ulisboa.pt:10451/24531","doi":null,"is_oa":false,"landing_page_url":"http://hdl.handle.net/10451/24531","pdf_url":null,"source":{"id":"https://openalex.org/S4306402433","display_name":"Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"master thesis"},"volume":null,"type":"dissertation","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Gon\u00e7alves, Rui Miguel Barbeiro","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Gon\u00e7alves, Rui Miguel Barbeiro","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":true,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.8500000238418579},{"id":"https://openalex.org/keywords/ctla-4","display_name":"CTLA-4","score":0.9430000185966492},{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.9990000128746033},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":0.8579999804496765},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.9419999718666077},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.7860000133514404},{"id":"https://openalex.org/keywords/tumor-immune-evasion","display_name":"tumor immune evasion","score":0.7519999742507935},{"id":"https://openalex.org/keywords/costimulatory-receptors","display_name":"costimulatory receptors","score":0.8849999904632568},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.7459999918937683},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.6970000267028809},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.6520000100135803}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7053999900817871},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.3149000108242035},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.2687000036239624},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.266400009393692},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2506999969482422},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.22339999675750732},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.2087000012397766},{"id":"https://openalex.org/C18762648","wikidata":"https://www.wikidata.org/wiki/Q42213","display_name":"Work (physics)","level":2,"score":0.20239999890327454},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.19979999959468842},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.19040000438690186}],"mesh":[],"locations_count":1,"locations":[{"id":"pmh:oai:repositorio.ulisboa.pt:10451/24531","doi":null,"is_oa":false,"landing_page_url":"http://hdl.handle.net/10451/24531","pdf_url":null,"source":{"id":"https://openalex.org/S4306402433","display_name":"Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"master thesis"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2066671159","https://openalex.org/W4382983356","https://openalex.org/W2069592230","https://openalex.org/W2322119923","https://openalex.org/W2769886328","https://openalex.org/W2954890231","https://openalex.org/W1587414944","https://openalex.org/W1997104993","https://openalex.org/W3162575990","https://openalex.org/W2902450096"],"abstract_inverted_index":{"Cancer":[0],"therapy":[1],"is":[2],"evolving":[3],"from":[4],"relatively":[5],"non-specific":[6],"strategies,":[7],"such":[8],"as":[9,76,98,153,155,164],"surgery,":[10],"radiotherapy":[11],"and":[12,52,60,80,94,115,133,192,195,215,230],"chemotherapy,":[13],"to":[14,33,58,82,188,232],"more":[15],"targeted":[16,37],"approaches.":[17],"The":[18],"understanding":[19],"that":[20,43,67],"the":[21,34,41,49,53,56,102,128,134,175,185,206,218,228,236],"immune":[22,50,88,147,189,210],"system":[23],"plays":[24],"a":[25,224,246],"dual":[26],"role":[27],"in":[28,127,178,209,217,242,245],"tumor":[29],"progression":[30],"has":[31,55,138],"led":[32],"development":[35,197],"of":[36,78,91,104,130,171,200,220,227,239],"immunotherapies,":[38],"based":[39],"on":[40],"principle":[42],"tumors":[44,68],"can":[45],"be":[46,233],"recognized":[47],"by":[48],"system,":[51],"latter":[54],"ability":[57],"regulate":[59],"even":[61],"eliminate":[62],"tumors.":[63],"Is":[64],"now":[65],"clear":[66],"co-opt":[69],"certain":[70],"physiologic":[71],"immunosuppressor":[72],"mechanisms,":[73,87],"using":[74],"them":[75],"means":[77],"escape":[79],"resistance":[81],"immune-mediated":[83],"destruction.":[84],"Among":[85],"these":[86,167,240],"checkpoints":[89,148],"are":[90,149,156,198],"special":[92],"importance,":[93],"have":[95,122],"been":[96,140],"investigated":[97],"therapeutic":[99],"targets,":[100],"through":[101],"use":[103],"blocking":[105],"monoclonal":[106],"antibodies.":[107],"Antibodies":[108],"targeting":[109],"Cytotoxic":[110],"T-lymphocyte":[111],"antigen":[112],"4":[113],"(CTLA-4)":[114],"Programmed":[116],"cell":[117],"death":[118],"protein":[119],"1":[120],"(PD-1)":[121],"already":[123,139,150],"shown":[124],"important":[125],"benefits":[126],"treatment":[129],"several":[131,161],"cancers,":[132],"first-in-class":[135],"Ipilimumab":[136],"(anti-CTLA-4)":[137],"approved":[141],"for":[142,165,235],"advanced":[143],"melanoma":[144],"treatment.":[145],"Other":[146],"under":[151],"investigation,":[152],"well":[154],"co-stimulatory":[157],"receptors.":[158],"Strategies":[159],"combining":[160,166],"immunomodulatory":[162],"agents,":[163],"with":[168],"other":[169],"types":[170],"therapies,":[172],"might":[173],"become":[174],"most":[176],"effective":[177],"obtaining":[179],"clinical":[180,243],"responses.":[181],"Unfortunately,":[182],"not":[183],"all":[184],"patients":[186],"respond":[187],"checkpoint":[190,211],"blockade,":[191],"patient":[193],"selection":[194],"biomarker":[196],"fields":[199],"great":[201],"investigation.":[202],"This":[203],"review":[204],"highlights":[205],"advances":[207],"achieved":[208],"targeting,":[212],"notably":[213],"CTLA-4":[214],"PD-1,":[216],"set":[219],"cancer":[221],"immunotherapy,":[222],"including":[223],"brief":[225],"discussion":[226],"application":[229],"challenges":[231],"overcome":[234],"wider":[237],"implementation":[238],"agents":[241],"practice":[244],"near":[247],"future.":[248]},"counts_by_year":[],"updated_date":"2026-09-01T08:31:24.195828","created_date":"2025-10-10T00:00:00"}